Memphasys Ltd (AU:MEM) has released an update.
Memphasys Limited is making strides in the assisted reproductive technology market with its Felix™ System, which is now available in Japan and soon targeting Europe. The company is also advancing in equine fertility studies and developing a rapid oxidative stress measurement system, RoXsta™, to broaden its product applications. Recent financial efforts, including capital raising and securing loans, support these initiatives, positioning Memphasys for significant market growth.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
